Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs) Abstract #1492

Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.
Aim(s): We aimed to validate our prognostic score for GI-NECs (liver metastases, alkaline phosphatase, lactate dehydrogenase, ECOG performance status (PS) and Ki67; Lamarca et al, ASCO 2015).
Materials and methods: We prospectively identified all consecutive patients (pts) diagnosed with GI-NECs seen at The Christie (July’14-Nov’15). Our previously designed score was applied. Cox regression and Kaplan Meier were used for survival analysis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca

To read results and conclusion, please login ...

Further abstracts you may be interested in

#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Hearn K, Teo L, Bernstone G, Johnson S, ...
#408 Expression of Cocaine- and Amphetamine-Regulated Transcript is Associated with Worse Survival in Small Bowel Carcinoid Tumors
Introduction: Cocaine- and amphetamine-regulated transcript (CART) peptide acts both as a neurotransmitter and hormone. We recently demonstrated that CART is expressed in several types of neuroendocrine tumors.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Kalle Landerholm
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
#470 Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET
Introduction: Today, grading, and thereby choice of treatment strategy for patients with neuroendocrine (NE) tumors, is mainly based on the proliferation index, Ki-67. As a supplement to this pathological evaluation, a whole body image analysis could be of value.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MSc, PhD Tina Binderup
#575 Does the ENETS TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours?
Introduction: A TNM staging system was designed by ENETS to stage small bowel NETs .(SBNETs)
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Clinical
Presenting Author: Dr Rajaventhan Srirajaskanthan
Keywords: Staging